title: Targeted delivery systems for oligonucleotide therapeutics.
abstract: Oligonucleotides including antisense oligonucleotides and siRNA are emerging as promising therapeutic agents against a variety of diseases. Effective delivery of these molecules is critical to their successful clinical application. Targeted systems can greatly improve the efficiency and specificity of oligonucleotides delivery. Meanwhile, an effective delivery system must successfully overcome a multitude of biological barriers to enable the oligonucleotides to reach the site of action and access their biological targets. Several delivery strategies based on different platform technologies and different targeting ligands have been developed to achieve these objectives. This review aims at providing a summary and perspective on recent progress in this very active area of research.
authors.affiliation: Department of Chemical and Biomolecular Engineering, College of Pharmacy, The Ohio State University, Columbus, Ohio, USA.
authors.forename: Bo
authors.initials: B
authors.lastname: Yu
authors.forename: Xiaobin
authors.initials: X
authors.lastname: Zhao
authors.forename: L James
authors.initials: LJ
authors.lastname: Lee
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Lee
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D002352:Carrier Proteins / Q000187:drug effects; D004337:Drug Carriers; D016503:Drug Delivery Systems; D004355:Drug Stability; D058973:Folate Receptors, GPI-Anchored; D005492:Folic Acid / Q000008:administration & dosage / Q000493:pharmacokinetics; D005822:Genetic Vectors; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage / Q000493:pharmacokinetics; D008024:Ligands; D008074:Lipoproteins / Q000008:administration & dosage / Q000493:pharmacokinetics; D008081:Liposomes; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy; D009841:Oligonucleotides / Q000008:administration & dosage* / Q000627:therapeutic use; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage / Q000627:therapeutic use; D010455:Peptides / Q000008:administration & dosage / Q000493:pharmacokinetics; D034741:RNA, Small Interfering / Q000008:administration & dosage / Q000627:therapeutic use; D011956:Receptors, Cell Surface / Q000187:drug effects; D014018:Tissue Distribution; D014168:Transferrin / Q000008:administration & dosage / Q000493:pharmacokinetics
chemical_list: D000911:Antibodies, Monoclonal; D002352:Carrier Proteins; D004337:Drug Carriers; D058973:Folate Receptors, GPI-Anchored; D018796:Immunoconjugates; D008024:Ligands; D008074:Lipoproteins; D008081:Liposomes; D009841:Oligonucleotides; D016376:Oligonucleotides, Antisense; D010455:Peptides; D034741:RNA, Small Interfering; D011956:Receptors, Cell Surface; D014168:Transferrin; D005492:Folic Acid